Literature DB >> 11606619

Psychogenomics: opportunities for understanding addiction.

E J Nestler1.   

Abstract

The term psychogenomics is used here to describe the process of applying the powerful tools of genomics and proteomics to achieve a better understanding of the biological substrates of normal behavior and of diseases of the brain that manifest themselves as behavioral abnormalities. Applying psychogenomics to the study of drug addiction will lead to the identification of genes and their protein products that control the reward pathways of the brain and their adaptations to drugs of abuse, as well as variations in these genes that confer genetic risk for addiction and related disorders. The ultimate goal is to use this information to develop more effective treatments for these disorders as well as objective diagnostic tools, preventive measures, and eventually cures.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11606619      PMCID: PMC6762799     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  37 in total

Review 1.  DeltaFosB: a sustained molecular switch for addiction.

Authors:  E J Nestler; M Barrot; D W Self
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

Review 2.  Neurofibromatosis type 1.

Authors:  L F Parada
Journal:  Biochim Biophys Acta       Date:  2000-07-31

3.  Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production.

Authors:  P Guidetti; V Charles; E Y Chen; P H Reddy; J H Kordower; W O Whetsell; R Schwarcz; D A Tagle
Journal:  Exp Neurol       Date:  2001-06       Impact factor: 5.330

4.  Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.

Authors:  R Yan; M J Bienkowski; M E Shuck; H Miao; M C Tory; A M Pauley; J R Brashier; N C Stratman; W R Mathews; A E Buhl; D B Carter; A G Tomasselli; L A Parodi; R L Heinrikson; M E Gurney
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

5.  DARPP-32: regulator of the efficacy of dopaminergic neurotransmission.

Authors:  A A Fienberg; N Hiroi; P G Mermelstein; W Song; G L Snyder; A Nishi; A Cheramy; J P O'Callaghan; D B Miller; D G Cole; R Corbett; C N Haile; D C Cooper; S P Onn; A A Grace; C C Ouimet; F J White; S E Hyman; D J Surmeier; J Girault; E J Nestler; P Greengard
Journal:  Science       Date:  1998-08-07       Impact factor: 47.728

Review 6.  Novel strategies to probe the functions of serotonin receptors.

Authors:  K L Stark; R S Oosting; R Hen
Journal:  Biol Psychiatry       Date:  1998-08-01       Impact factor: 13.382

7.  Overview of the most prevalent hypothalamus-specific mRNAs, as identified by directional tag PCR subtraction.

Authors:  K M Gautvik; L de Lecea; V T Gautvik; P E Danielson; P Tranque; A Dopazo; F E Bloom; J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

8.  Gene expression in human alcoholism: microarray analysis of frontal cortex.

Authors:  J M Lewohl; L Wang; M F Miles; L Zhang; P R Dodd; R A Harris
Journal:  Alcohol Clin Exp Res       Date:  2000-12       Impact factor: 3.455

Review 9.  PNA oligomers as tools for specific modulation of gene expression.

Authors:  M Pooga; T Land; T Bartfai; U Langel
Journal:  Biomol Eng       Date:  2001-06

Review 10.  Dissection of behavior and psychiatric disorders using the mouse as a model.

Authors:  L M Tarantino; M Bucan
Journal:  Hum Mol Genet       Date:  2000-04-12       Impact factor: 6.150

View more
  10 in total

Review 1.  A behavioral/systems approach to the neuroscience of drug addiction.

Authors:  Francis J White
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

2.  Repeated cocaine self-administration causes multiple changes in rat frontal cortex gene expression.

Authors:  Willard M Freeman; Karen Brebner; Kruti M Patel; Wendy J Lynch; David C S Roberts; Kent E Vrana
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

Review 3.  Neurodevelopment, impulsivity, and adolescent gambling.

Authors:  R Andrew Chambers; Marc N Potenza
Journal:  J Gambl Stud       Date:  2003

4.  Ethical and human rights imperatives to ensure medication-assisted treatment for opioid dependence in prisons and pre-trial detention.

Authors:  R Douglas Bruce; Rebecca A Schleifer
Journal:  Int J Drug Policy       Date:  2008-01-15

5.  Methamphetamine modulates gene expression patterns in monocyte derived mature dendritic cells: implications for HIV-1 pathogenesis.

Authors:  Supriya D Mahajan; Zihua Hu; Jessica L Reynolds; Ravikumar Aalinkeel; Stanley A Schwartz; Madhavan P N Nair
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

6.  A method for single-session cocaine self-administration in the mouse.

Authors:  Christopher M Olsen; Danny G Winder
Journal:  Psychopharmacology (Berl)       Date:  2006-04-27       Impact factor: 4.530

7.  The influence of adolescent nicotine exposure on ethanol intake and brain gene expression.

Authors:  Constanza P Silva; William J Horton; Michael J Caruso; Aswathy Sebastian; Laura C Klein; Istvan Albert; Helen M Kamens
Journal:  PLoS One       Date:  2018-06-18       Impact factor: 3.240

8.  Histone H3 dopaminylation in ventral tegmental area underlies heroin-induced transcriptional and behavioral plasticity in male rats.

Authors:  Sasha L Fulton; Swarup Mitra; Ashley E Lepack; Jennifer A Martin; Andrew F Stewart; Jacob Converse; Mason Hochstetler; David M Dietz; Ian Maze
Journal:  Neuropsychopharmacology       Date:  2022-01-29       Impact factor: 8.294

9.  Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent.

Authors:  Laith N Al-Eitan; Saied A Jaradat; Steve Ys Su; Guan K Tay; Gary K Hulse
Journal:  Pharmgenomics Pers Med       Date:  2012-09-07

10.  Genes and (common) pathways underlying drug addiction.

Authors:  Chuan-Yun Li; Xizeng Mao; Liping Wei
Journal:  PLoS Comput Biol       Date:  2007-11-20       Impact factor: 4.475

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.